New treatments for hepatitis B and C in children and adolescents

  • Patrick Gerner
Part of the Birkhäuser Advances in Infectious Diseases book series (BAID)


The treatment of chronic viral hepatitis is a rapidly evolving field. Therapy for chronic hepatitis B is indicated at times of high viral replication, as long as the patient’s aminotransferase levels are increased by more than twice the norm, and when hepatitis B e antigen (HBeAg) is positive. The treatment options for chronic hepatitis B include interferon-alpha and the nucleoside analogues lamivudine and adefovir dipivoxil. Between 26% and 38% of patients respond to treatment with interferon-alpha and nucleoside analogues; from 17% to 36% respond with antibodies to HBeAg (anti-HBe) seroconversion after 1 year. With seroconversion, HBeAg disappears and there is a dramatic decrease in HBV-DNA and usually in the aminotransferases. Further development of nucleoside analogues promises to increase the effectiveness of the therapy. Complete recovery, with conversion to antibodies to hepatitis B surface antigen (anti-HBs), occurs in about 5% of patients only after interferon-alpha therapy. The success of treatment is influenced by factors such as the origins of infection, the viral load before therapy, and the intensity of liver inflammation. Without therapy, the rate of seroconversion to anti-HBe ranges from 2.5% to 11% a year. It is becoming evident that patients with fulminant hepatitis B benefit from treatment with lamivudine. In contrast to hepatitis B, the treatment goal for chronic hepatitis C is the patient’s full recovery. Currently, depending on the HCV genotype, the combination therapy of interferon-alpha and ribavirin administered for 6–12 months has proven effective. Approximately 80% of children are infected with genotype 1a or 1b. They have a recovery rate of 45%. Genotypes 2 or 3 respond much better to treatment. More than 84% of patients can be successfully treated. Genotype 4 is relatively rare and appears to respond to treatment like genotype 1. Under certain circumstances, unsuccessfully treated patients can be treated a second time, after a number of years, with another interferon-alpha, e.g., natural human alpha interferon (Multiferon®) or consensus interferon (Inferax®) plus ribavirin. In addition, new medications such as protease and polymerase inhibitors are currently being tested in adult patients and should be available in the next few years.


Chronic Hepatitis Nucleoside Analogue Fulminant Hepatitis Autoimmune Thyroiditis Adefovir Dipivoxil 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Thomas HC, Lemon S, Zuckerman AJ (eds) (2005) Viral hepatitis, 3rd edn. Blackwell Publishing, OxfordGoogle Scholar
  2. 2.
    Shapiro CN, Margolis HS (1990) Hepatitis B epidemiology and prevention. Epidemiol Rev 12: 221–227PubMedGoogle Scholar
  3. 3.
    Grob P, Jilg W, Bornhak H, Gerken G, Gerlich W, Gunther S, Hess G, Hudig H, Kitchen A, Margolis H et al (2000) Serological pattern “anti-HBc alone”. J Med Virol 62: 450–455PubMedCrossRefGoogle Scholar
  4. 4.
    Bortolotti F, Jara P, Barbera C, Gregorio GV, Vegnente A, Zancan L, Hierro L, Crivellaro C, Vergani GM, Iorio R et al (2000) Long term effect of alpha interferon in children with chronic hepatitis B. Gut 46: 715–718PubMedCrossRefGoogle Scholar
  5. 5.
    Sokal EM, Wirth S, Goyens P, Depreterre A, Cornu C (1993) Interferon alfa-2b therapy in children with chronic hepatitis B. Gut 34: 87–90Google Scholar
  6. 6.
    Sokal EM, Conjeevaram HS, Roberts EA, Alvarez F, Bern EM, Goyens P, Rosenthal P, Lachaux A, Shelton M, Sarles J, Hoofnagle J (1998) Interferon alpha therapy for chronic hepatitis B in children: a multinational randomized controlled trial. Gastroenterology 114: 988–995PubMedCrossRefGoogle Scholar
  7. 7.
    Lai CL, Dienstag J, Schiff E, Leung NW, Atkins M, Hunt C, Brown N, Woessner M, Boehme R, Condreay L (2003) Prevalence and clinical correlates of YMDD variants during lamivudine therapy for patients with chronic hepatitis B. Clin Infect Dis 36: 687–696PubMedCrossRefGoogle Scholar
  8. 8.
    Vo Thi Diem H, Bourgois A, Bontems P, Goyens P, Buts JP, Nackers F, Tonglet R, Sokal EM (2005) Chronic hepatitis B infection: long term comparison of children receiving interferon alpha and untreated controls. J Pediatr Gastroenterol Nutr 40: 141–145PubMedCrossRefGoogle Scholar
  9. 9.
    Janssen HL, van Zonneveld M, Senturk H, Zeuzem S, Akarca US, Cakaloglu Y, Simon C, So TM, Gerken G, de Man RA et al (2005) Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365: 123–129PubMedCrossRefGoogle Scholar
  10. 10.
    Figlerowicz M, Kowala-Piaskowska A, Filipowicz M, Bujnowska A, Mozer-Lisewska I, Sluzewski W (2005) Efficacy of lamivudine in the treatment of children with chronic hepatitis B. Hepatol Res 31: 217–222PubMedCrossRefGoogle Scholar
  11. 11.
    Hartman C, Berkowitz D, Shouval D, Eshach-Adiv O, Hino B, Rimon N, Satinger I, Kra-Oz T, Daudi N, Shamir R (2003) Lamivudine treatment for chronic hepatitis B infection in children unresponsive to interferon. Pediatr Infect Dis J 22: 224–249PubMedCrossRefGoogle Scholar
  12. 12.
    Jonas MM, Mizerski J, Badia IB, Areias JA, Schwarz KB, Little NR, Greensmith MJ, Gardner SD, Bell MS, Sokal EM (2002) International Pediatric Lamivudine Investigator Group. Clinical trial of lamivudine in children with chronic hepatitis B. N Engl J Med 346: 1706–1713PubMedCrossRefGoogle Scholar
  13. 13.
    Gerner P, Wirth S, Wintermeyer P, Walz A, Jenke A (2006) Prevalence of hepatitis C virus infection in children admitted to an urban hospital. J Infect 52: 305–308PubMedCrossRefGoogle Scholar
  14. 14.
    Vandelli C, Renzo F, Romano L, Tisminetzky S, De Palma M, Stroffolini T, Ventura E, Zanetti A (2004) Lack of evidence of sexual transmission of hepatitis C among monogamous couples: results of a 10-year prospective follow-up study. Am J Gastroenterol 99: 855–859PubMedCrossRefGoogle Scholar
  15. 15.
    Jacobson KR, Murray K, Zellos A, Schwarz KB (2002) An analysis of published trials of interferon monotherapy in children with chronic hepatitis C. J Pediatr Gastroenterol Nutr 34: 52–58PubMedCrossRefGoogle Scholar
  16. 16.
    Wirth S, Lang T, Gehring S, Gerner P (2002) Recombinant alfa-interferon plus ribavirin therapy in children and adolescents with chronic hepatitis C. Hepatology 36: 1280–1284PubMedCrossRefGoogle Scholar
  17. 17.
    Wirth S, Pieper-Boustani H, Lang T, Ballauff A, Kullmer U, Gerner P, Wintermeyer P, Jenke A (2005) Peginterferon alfa-2b plus ribavirin treatment in children and adolescents with chronic hepatitis C. Hepatology 41: 1013–1018PubMedCrossRefGoogle Scholar
  18. 18.
    Gonzalez-Peralta RP, Kelly DA, Haber B, Molleston J, Murray KF, Jonas MM, Shelton M, Mieli-Vergani G, Lurie Y, Martin S et al (2005) Interferon alfa-2b in combination with ribavirin for the treatment of chronic hepatitis C in children: efficacy, safety, and pharmacokinetics. Hepatology 42: 1010–1018PubMedCrossRefGoogle Scholar
  19. 19.
    Ahn J, Flamm S (2004) Peginterferon-alpha(2b) and ribavirin. Expert Rev Anti Infect Ther 2: 17–25PubMedCrossRefGoogle Scholar

Copyright information

© Birkhäuser Verlag 2007

Authors and Affiliations

  • Patrick Gerner
    • 1
  1. 1.Children’s HospitalHELIOS Klinikum Wuppertal, Witten-Herdecke UniversityWuppertalGermany

Personalised recommendations